Question Bank › Proven engine, fuel already in the tank

Proven engine, fuel already in the tank

Proven engine, fuel already in the tank: a working growth driver plus already-held means to multiply it

Calls Tested
496
Answered YES
100
Hit Rate
20.2%
rare by design

MannKind Corporation (MNKD) — this company's answers

NO on the Q4 2023 call 2024-02-27 C
The model's full reasoning — Q4 2023 call → NO我们根据提供的文本内容来判断。问题要求判断管理层是否在同一部分业务上同时描述了(1)一个已被证明、已在产生收入的增长引擎,且其目前只占据了其潜力的一小部分;(2)公司已经拥有或已经确保的、正在用于扩大该引擎的资源。 在文本中,管理层提到了多个业务部分。我们需要找到同一部分业务同时满足这两个条件。 首先,关于Tyvaso DPI:管理层提到Tyvaso DPI的版税收入和合作制造收入在增长,但这是与United Therapeutics的合作,不是公司自己的产品。而且Tyvaso DPI是公司为UT制造的,公司只收取版税和制造费。管理层没有说这是公司自己的增长引擎,而是说这是公司收入的主要来源。但问题要求的是“同一部分业务”,并且是“增长引擎”且“已经产生实际业务”且“只占其潜力的一小部分”。对于Tyvaso DPI,管理层提到“我们正在尽可能多地制造”,但并没有说它只占了一小部分潜力,而是说它已经很大了。实际上,Tyvaso DPI是公司最大的收入来源,可能已经成熟。 其次,关于Afrezza和内分泌业务:管理层提到Afrezza净收入增长27%,并且说“我们从未见过比现在更好的时机”,但并没有明确说Afrezza只占其潜力的一小部分。管理层提到“我们相信我们可以让这个业务成为我们增长故事的核心支柱”,但这是未来展望。另外,管理层提到INHALE-1和INHALE-3试验将带来数据,但那是未来的数据,不是已经产生的。对于内分泌业务,管理层说“内分泌业务连续第二个季度盈利”,但并没有说它只占潜力的一小部分。 再次,关于MNKD-101(clofazimine)和MNKD-201(nintedanib):这些是管线资产,尚未产生收入,所以不符合“已经产生实际业务”的条件。 最后,关于Tyvaso DPI的制造能力:管理层提到“我们完成了高速灌装线的资格认证,将开始PPQ,希望生产更高产量”,但这是关于制造能力的,不是关于增长引擎的。 我们需要找到同一部分业务,管理层明确说它已经产生实际业务,并且只占其潜力的一小部分,同时公司已经拥有资源来扩大它。 在文本中,管理层多次提到Afrezza和内分泌业务。例如:“内分泌业务在2023年增长了32%,达到7000万美元,并在第四季度创造了2000万美元,连续第二个季度盈利贡献,年化运行率8000万美元。”但这里没有说它只占潜力的一小部分。管理层说“我们相信我们可以让这个业务成为我们增长故事的核心支柱”,但这是未来展望。 另外,管理层提到“我们正在等待INHALE-1和INHALE-3的数据”,这些数据将扩大市场潜力,但那是未来的。 关于Tyvaso DPI,管理层说“我们正在尽可能多地制造”,但并没有说它只占潜力的一小部分,而是说它已经很大了。 因此,似乎没有明确的部分同时满足两个条件。也许管理层提到了“我们将在2024年生产超过2500万剂和设备,并在2023年帮助了大约25000名患者使用MannKind生产的产品,这是历史上最多的。”但这是整体,不是特定引擎。 再仔细看,管理层提到“我们的内分泌业务连续第二个季度盈利”,但并没有说它只占潜力的一小部分。 或许关于Tyvaso DPI的制造能力,管理层说“我们完成了高速灌装线的资格认证,将开始PPQ,希望生产更高产量”,但这是关于制造能力的,不是关于增长引擎的。 因此,我认为答案是否定的。管理层没有明确描述一个已经产生实际业务且只占其潜力一小部分的增长引擎,同时公司已经拥有资源来扩大它。他们更多是在谈论未来的数据、管线等。 所以答案应为NO。

← Back to the full MNKD analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe BOTH of the following about the SAME part of the business, as one connected present-tense story? (1) A PROVEN, ALREADY-PRODUCING GROWTH ENGINE THAT IS STILL SMALL RELATIVE TO ITS ROOM. Management identifies a specific driver of growth — a product, service, offering, location type, customer relationship, market, asset, or capability, in whatever form fits the industry — that is ALREADY generating real business today (actual revenue, orders, customers, volumes, output, or usage in the recent period, described with concrete substance rather than as pipeline, plans, or market opportunity), and management conveys, directly or plainly in substance, that this driver has so far captured only a small part of what it can reach — because it is early in its rollout, present in only a fraction of the customers, sites, applications, or territory available to it, or recently started and still ramping — so that the reported results reflect only the beginning of what this engine is already doing. (2) THE MEANS TO MULTIPLY IT ARE ALREADY IN THE COMPANY'S HANDS. Management describes resources the company ALREADY possesses or has ALREADY secured that it is now using, or beginning to use, to scale that same driver up — in whatever form fits the business: cash or self-generated funds being deployed into it; capacity, facilities, inventory, or supply already built or secured that it can fill; an existing customer base, footprint, network, or channel through which it can be pushed; approvals, qualifications, or positions already held that permit its expansion; a repeatable formula, site type, or playbook already demonstrated that is now being replicated; or people and capability already in place being pointed at it. The multiplication must be presented as already underway or already resourced from what the company has — not dependent on raising outside money, winning approvals not yet obtained, or demand that has not yet appeared. Answer YES when both halves are present in management's own words and connected — the engine is real and producing now, its captured share of its own opportunity is still small, and the company is already applying means it already holds to make it bigger — so that the just-reported numbers describe a company visibly smaller than the one management is already building with its own resources. Answer NO if the growth driver is only a plan, pilot without real paying activity, launch with nothing yet sold, or market opportunity. NO if the driver is already mature, already the dominant established business running at its full reach, or already fully reflected in results with no meaningful room described. NO if scaling it depends chiefly on outside financing not yet raised, approvals not yet granted, partners not yet signed, or demand not yet visible. NO if the 'room ahead' is expressed only as a generic total-addressable-market statistic or big-market talk without management conveying how little of the accessible opportunity this driver has captured. NO if the expansion resources are only planned, budgeted for later, or contingent. NO if the company is chiefly defending weak results, cutting back, or promising a turnaround. NO if either half appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
NOAH Noah Holdings Limited Q1 2024 2024-05-30 D
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
LINC Lincoln Educational Services Corporation Q1 2024 2024-05-06 B+
ROCK Gibraltar Industries, Inc. Q1 2024 2024-05-01 B+
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
TNET TriNet Group, Inc. Q1 2024 2024-04-26 C
APYX Apyx Medical Corporation Q4 2023 2024-03-21 C
HUYA HUYA Inc. Q4 2023 2024-03-19 C
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
NICE NICE Ltd. Q4 2023 2024-02-22 B+
OUT Outfront Media Inc. Q4 2023 2024-02-21 C+
PUMP ProPetro Holding Corp. Q4 2023 2024-02-21 C+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
OPAD Offerpad Solutions Inc. Q3 2023 2023-11-01 C
APAM Artisan Partners Asset Management Inc. Q3 2023 2023-11-01 C+
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
FSBC Five Star Bancorp Q3 2023 2023-10-31 B
TGLS Tecnoglass Inc. Q2 2023 2023-08-08 A
PTLO Portillo's Inc. Q2 2023 2023-08-05 B
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
AFL Aflac Incorporated Q2 2023 2023-08-02 C+
NMR Nomura Holdings, Inc. Q1 2024 2023-08-02 D
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
M Macy's, Inc. Q4 2022 2023-03-02 D
TGT Target Corporation Q4 2022 2023-02-28 C
TOST Toast, Inc. Q4 2022 2023-02-16 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
HBAN Huntington Bancshares Incorporated Q4 2022 2023-01-20 B
WGO Winnebago Industries, Inc. Q1 2023 2022-12-16 D
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
BLZE Backblaze, Inc. Q3 2022 2022-11-11 D
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
SYY Sysco Corporation Q1 2023 2022-11-01 C+
KEY KeyCorp Q3 2022 2022-10-20 B+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
HLNE Hamilton Lane Incorporated Q1 2023 2022-08-02 C+
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
UPWK Upwork Inc. Q2 2022 2022-07-27 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
KFY Korn Ferry Q4 2022 2022-06-22 B
SE Sea Limited Q1 2022 2022-05-17 F
FLYW Flywire Corporation Q1 2022 2022-05-14 B+
ZVIA Zevia PBC Q1 2022 2022-05-12 B
IRTC iRhythm Technologies, Inc. Q1 2022 2022-05-07 C+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
RELY Remitly Global, Inc. Q4 2021 2022-03-02 B
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
VVV Valvoline Inc. Q1 2022 2022-02-09 C+
GTES Gates Industrial Corporation plc Q4 2021 2022-02-07 C+
SLQT SelectQuote, Inc. Q2 2022 2022-02-07 F
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
LOW Lowe's Companies, Inc. Q3 2021 2021-11-17 B+
KTB Kontoor Brands, Inc. Q3 2021 2021-11-04 A
LPTH LightPath Technologies, Inc. Q4 2021 2021-09-09 D
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
CPRX Catalyst Pharmaceuticals, Inc. Q2 2021 2021-08-10 C+
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+
LOPE Grand Canyon Education, Inc. Q2 2021 2021-08-08 C
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
ESRT Empire State Realty Trust, Inc. Q2 2021 2021-07-29 C+
TENB Tenable Holdings, Inc. Q2 2021 2021-07-27 A
JPM JPMorgan Chase & Co. Q2 2021 2021-07-13 A
CMTL Comtech Telecommunications Corp. Q1 2019 2018-12-07 B+
ADSK Autodesk, Inc. Q3 2019 2018-11-20 A
ALB Albemarle Corporation Q3 2018 2018-11-08 B
UMH UMH Properties, Inc. Q3 2018 2018-11-02 C+
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
AMGN Amgen Inc. Q3 2018 2018-10-30 B+
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
T AT&T Inc. Q3 2018 2018-10-24 C+
STM STMicroelectronics NV Q3 2018 2018-10-24 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
XOM Exxon Mobil Corporation Q2 2018 2018-07-27 C
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
LAUR Laureate Education, Inc. Q1 2018 2018-05-13 B+
NOVT Novanta Inc. Q4 2017 2018-05-12 B+
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
TOUR Tuniu Corporation Q4 2017 2018-03-14 D
UPLD Upland Software, Inc. Q4 2017 2018-03-08 C+
FI Fiserv, Inc. Q4 2017 2018-02-27 C
UNH UnitedHealth Group Incorporated Q4 2017 2018-01-16 A
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
UAA Under Armour, Inc. Q3 2017 2017-10-31 F
IR Ingersoll-Rand Plc Q3 2017 2017-10-25 B
MKTX MarketAxess Holdings Inc. Q3 2017 2017-10-25 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
BCE BCE Inc. Q2 2017 2017-08-05 B+
CCOI Cogent Communications Holdings, Inc. Q2 2017 2017-08-03 B
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
LBTYK Liberty Global's Q1 2016 2016-05-10 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
WK Workiva Inc. Q4 2015 2016-03-01 B

How the model reasoned

NMR · Q1 2024 → YESThe question is whether management describes BOTH a proven, already-producing growth engine that's still small relative to its room, AND the means to multiply it already in the company's hands, as one...YES The transcript shows management describing the Retail business as a growth engine that's already producing real results (net revenue up 22%, income up 133% after reorganization in March, recurring and flow revenue benefits starting to appear) but still small relative to its room (only 1,600 partners deployed out of a much larger potential base, with Q-on-Q progress negative from uncontacted clients, and explicit statements like "if we can broaden our partner base, then we will start to see the benefit" and "we have not been able to contact all clients").
OWL · Q2 2021 → YESThe question is whether management describes BOTH a proven, already-producing growth engine that's still small relative to its room, AND the means to multiply it already in the company's hands, as one...YES The transcript shows management describing Direct Lending as a proven growth engine already producing real activity ($5.1 billion gross deployments in the quarter, $31 billion AUM) while still small relative to its opportunity (explicitly "very small relative to total market opportunity" with a $300 billion market and $1. 5 trillion PE dry powder). They connect this directly to the means already in hand: existing sponsor relationships (500), $8.
WRBY · Q1 2024 → YESThe question is: Does management describe BOTH of a proven, already-producing growth engine that's still small relative to its room, AND the means to multiply it already in the company's hands, as one...

More from the question bank

Sizing the constraint out loudFixed price, unfixed volumeThe lull that never cameFront, middle, and back of the business all Doing it our way nowThe hard part is already doneAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.